Role of antibiotic stewardship in extending the age of modern medicine by Mendelson, M
CONTINUING MEDICAL EDUCATION
414       May 2015, Vol. 105, No. 5
Antibiotic resistance is threatening modern medicine. Overuse and misuse of antibiotics is driving resistance to such an extent that we have entered the 
post-antibiotic era, where some multidrug- and pandrug-resistant bacterial infections are no longer treatable. If the situation is not reversed, 
10 million people will die annually of drug-resistant infections by 2050. More than just a question of mortality, such infections are causing the 
closure of wards, cancellation of operations, and interference with other common medical procedures that rely on antibiotics for their success. The 
response to this crisis requires co-ordinated international action with increased surveillance of bacterial resistance, infection prevention, and antibiotic 
stewardship, i.e. access to affordable, quality-assured antibiotics prescribed appropriately. This review describes antibiotic stewardship at the individual 
patient and programmatic level, which must be adopted by every prescriber if we are to preserve modern medicine for future generations.
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Antibiotic overuse and 
misuse drives resistance
A common misconception suggests that antibiotic 
resistance (ABR) is a result of the introduction of 
antibiotics from the 1940s onwards. ABR is, however, 
an ancient phenomenon; bacterial resistance genes have been 
identified in ice samples dating back 30  000 years.[1] Naturally 
acquired bacterial resistance genes are propagated by the survival 
advantage they confer on bacteria in response to attack from naturally 
occurring antibacterial proteins produced by other bacteria and fungi. 
Resistance mechanisms may also be acquired through horizontal gene 
transfer of mobile genetic elements on plasmids (circular pieces of 
extrachromosomal DNA) that carry the resistance gene(s) between 
bacteria.[2] A bacterium that possesses a way of resisting an antibiotic 
attack has a survival advantage over bacteria that do not. In the 
presence of an antibiotic to which that bacterium is resistant, the 
resistant bacterium will be selected out in favour of bacteria that 
are sensitive to the antibiotic. Hence, Darwinian natural selection is 
being played out. The antibiotics first discovered by Fleming did not 
create ABR – their use has provided a survival advantage to resistant 
bacteria. It therefore follows that the more antibiotics one uses, the 
more resistance will develop. 
This paradox threatens modern medicine, which relies so 
intimately on antibiotics for its successes. Estimates suggest that 
antibiotics have resulted in an additional 20 years of life expectancy.[3] The 
use of antibiotics to prevent surgical site infection enables safe surgical 
procedures that would otherwise carry significant morbidity and 
mortality.[4] Antibiotics form an integral part of the management of 
high-risk patients, such as the critically ill in intensive care units, 
those who are immunosuppressed as a result of transplantation, 
chemotherapy or HIV, and those with a broad spectrum of bacterial 
infection – from sepsis to septic shock. For every hour a person 
with septic shock is not being treated with an antibiotic to which the 
bacteria are sensitive, mortality increases by 7.8%.[5] Mortality from 
antibiotic-resistant compared with antibiotic-sensitive infections is 
increased, as is morbidity and length of hospital stay.[6] Furthermore, 
resistance comes with heavy financial costs to healthcare systems; 
second- and third-line antibiotics are more expensive.[7] Therefore, 
to limit resistance we face a critical balance between the need to 
use antibiotics as life-saving medicines and the need to ensure their 
appropriate use. 
We are currently in a state of crisis. Overuse and misuse of 
antibiotics over the past 70 years has propelled us into a post-
antibiotic era. Untreatable, pandrug-resistant bacterial infections 
are increasingly common,[8,9] and colonisation or infection with 
multidrug-resistant (MDR) bacteria has changed the risk profile of 
patients to such an extent that medical and surgical procedures may 
no longer be considered.[10] We have engendered this global disaster 
by disregarding the basic tenet of antibiotic prescribing, i.e. ‘access not 
excess’, and by forgetting that, ecologically, antibiotics are a common 
pooled resource whose use, and exclusion of use through resistance, 
affects the global population rather than merely our patients or 
ourselves. Also, individuals and populations travel, and with them 
resistant bacteria such as New Delhi metallobetalactamase-1-
(NDM-1)[11] or Klebsiella pneumoniae carbapenemase (kpc)[12] in 
Gram-negative bacteria, which has ensured the global spread of MDR 
bacteria to new, susceptible populations. People in low- and middle-
income countries (LMICs), where healthcare systems are already 
overstretched owing to the high burden of infection, are at an even 
greater disadvantage than those in high-income countries (HICs). 
Global response to antibiotic resistance
An international response is required to answer this crisis. The World 
Health Organization (WHO), whose previous calls for action went 
largely unheeded,[13,14] has developed a draft global action plan (GAP) 
as a result of wide stakeholder consultation that will be presented at 
the 68th World Health Assembly in Geneva, Switzerland in May 2015 
for adoption.[15] GAP mandates member states to produce national 
strategic plans to combat antimicrobial resistance (AMR), with specific 
emphasis on antibacterial resistance.[16,17] Simply put, there are three 
fundamental pillars of any strategy that must be strengthened to 
combat ABR. Firstly, through strengthened surveillance and reporting, 
we need to learn what the resistance profile of the bacteria in our 
local environment (community and healthcare settings) is to enable 
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appropriate choice of an antibiotic that will be 
active against a given infection. Secondly, when 
a bacterium that requires treatment is identified 
or an empiric antibiotic(s) is needed before its 
identification, we must optimise the use of that 
antibiotic to maximise its action (antibiotic 
stewardship (ABS)). Lastly, we need to pre-
vent infection before it occurs by attending 
to social determinants that drive infectious 
diseases, such as water supply and sanitation, 
and increase access to and coverage with 
vaccines. Rigorous infection control practice in 
healthcare settings to prevent transmission of 
resistant bacteria from patient to patient must 
be adopted, chief among which is rigorous 
hand hygiene. Infection prevention as it relates 
to ABR is comprehensively reviewed in this 
CME series by Brink[18] and Whitelaw.[19]
The required response is as pertinent to 
animal and agricultural sectors as it is to 
human health. As an estimated 80% of all 
antibiotic use is in animals[20] and its association 
with acquisition of resistant bacteria by humans 
is becoming increasingly clear,[21] we disregard 
the impact of antibiotic use in the animal sector 
at our peril. However, for the purposes of this 
review, I concentrate on the essential elements 
of ABS as it relates to bacterial infections other 
than tuberculosis in humans. 
Antibiotic stewardship 
at the individual patient 
level
At an individual patient level, a single 
fundamental question needs to be asked 
before any antibiotic is prescribed: ‘Does this 
patient have a bacterial infection that requires 
an antibiotic?’ (Fig. 1.) While particularly 
pertinent to primary care prescribers and the 
continued unnecessary use of antibiotics for 
viral upper respiratory tract infections (URTIs), 
it applies equally to febrile patients admitted 
to healthcare institutions at all levels. The 
identification of intensive care patients in the 
public and private sectors in South Africa (SA) 
who were on up to 10 different antibiotics 
concurrently, testifies to this and the need to 
realise that collective action is needed.[22] 
Although simpler for patients with a 
clear source of infection, the question of 
whether a patient has a bacterial infection 
becomes more complex when related to an 
undifferentiated fever, i.e. one that lacks a 
clear site of origin. Fear of missing a bacterial 
infection is a strong motivator for prescribing 
antibiotics,[23] whereas having access to 
diagnostic tests, ideally those at point-of-
care (POC) to help differentiate the cause 
of fever, increases appropriate antibiotic use.
[24,25] Access to a POC malaria rapid diagnostic 
test in Zambia led to a four-fold reduction in 
inappropriate antimalarial prescribing, and 
a five-fold increase in the appropriate use of 
antibiotics for pneumonia.[25] Furthermore, 
when diagnostic and resistance information 
is provided in a single test, not only may 
a diagnosis be established, but the time to 
appropriate antibiotic use reduced. The 
automated real-time nucleic acid amplification 
system Xpert MTB/RIF, which can confirm 
the presence of tuberculosis and its sensitivity 
to rifampicin within 2 hours, is one such 
example.[26] Similarly, rapid POC or close to 
POC non-culture-based tests for antibiotic-
resistant bacteria other than Mycobacterium 
tuberculosis are urgently needed, particularly 
in LMICs with poor access to assured quality 
diagnostic services.
When the source of infection is clear, but 
the microbial aetiology is not, biomarkers such 
as C-reactive protein (CRP) and pro calcitonin 
(PCT) may be useful tools for specific 
infections. Both CRP[27,28] and PCT[29,30] have 
demonstrated utility in differentiating bacterial 
from viral acute respiratory infection (ARI) in 
developed countries, and for PCT its use has 
been estimated to confer substantial economic 
gains (USD1.6 billion (ZAR18.8 billion) 
savings if used across the US health sector) 
in HICs.[31] In a high tuberculosis-prevalence 
country such as SA, the utility of CRP and 
PCT is less clear for ARI, as both are increased 
in tuberculosis. Furthermore, in a resource-
challenged healthcare setting, PCT, which 
currently costs in excess of ZAR300 per test, 
is costly, particularly when used incorrectly.[32]
Once the decision has been made to 
treat with an antibiotic, it is imperative that, 
whenever possible, adequate specimens are 
sent to the laboratory to enable identification 
of the bacteria causing infection and, 
critically, its sensitivity profile to antibiotics 
(the antibiogram) before the antibiotic 
is administered. The likelihood of adverse 
effects of broad-spectrum antibiotics, whose 
use is commonly indicated at the start of 
treatment, is greater than those of directed, 
narrow-spectrum antibiotics that can be used 
once sensitivities are known. An antibiogram 
is a prerequisite for safe de-escalation from 
a broad- to narrow-spectrum antibiotic. 
Without it, the prescriber runs the risk of 
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Respiratory tract - S. pneumoniae
Is there evidence of bacterial infection?
·  Fever
· Specific organ dysfunction (e.g. dysuria, meningism, productive cough)
·  Leucocytosis with neutrophilia and left shift, toxic granulation (± biomarkers suggestive of bacterial infection)
Fig. 1. Algorithm to determine whether a patient has a bacterial infection.
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using a resistant or partially active antibiotic, which may negatively 
affect the patient’s treatment. Whenever possible, a specimen from the 
probable site of infection should be sent to the laboratory. If no focus is 
evident, one or more correctly taken blood cultures are required (Fig. 
1).[33] For blood cultures, the volume of blood inoculated is critical in 
determining yield. In an unselected cohort of adult patients requiring 
blood culture in the Emergency Department at Groote Schuur Hospital, 
Cape Town, all cultures were negative if <2 mL of blood were inoculated. 
The yield doubled if 10 - 12 mL were inoculated compared with 2 - 8 mL 
(T Boyles – personal communication).
Once appropriate cultures have been sent, considering the checklist 
presented in Box 1 can optimise prescribing. The empiric choice of 
an antibiotic is determined by the probable identity of the infecting 
organism and the likelihood of it carrying a resistance gene. For 
example, Gram-negative Enterobacteriaceae (Escherichia coli and 
Klebsiella pneumoniae) commonly cause urinary tract infections 
(UTIs); therefore, an antibiotic with a spectrum of activity against 
Gram-negative bacteria is advised. Resistance to commonly used 
Gram-negative antibiotics for UTI in community-acquired infections 
in SA is generally still low, but does vary geographically. Therefore, 
an antibiotic such as an aminoglycoside or ciprofloxacin would be 
an acceptable empiric choice. However, in SA, hospital-acquired UTI 
due to Enterobacteriaceae is characterised by high levels of extended-
spectrum beta-lactamase production, rendering many resistant to first-
line antibiotics, and forcing the use of second-line, broader-spectrum 
antibiotics. 
The optimal dose of an antibiotic depends on a number of factors, 
including the pharmacodynamic and pharmacokinetic properties 
associated with individual antibiotics, the patient’s body weight, renal 
function, and, less commonly, hepatic function. Dosing of many 
antibiotics is weight dependent, e.g. vancomycin (Box 2), whose 
dosing frequency must be guided by therapeutic drug monitoring. 
A lack of attention to weight-based dosing and renally determined 
dosing frequency represents a common antibiotic prescribing pitfall. 
Pharmacokinetics play an especially important role in the critically ill 
patient in whom the volume of distribution may increase, augmented 
renal clearance may be present, and hypoalbuminaemia may alter the 
ratio of bound v. unbound antibiotic. Hence, dose must be carefully 
considered to optimise the effect of the antibiotic, particularly in 
those who are critically ill.
For many prescribers, determining the duration of an antibiotic course 
is a matter of what is familiar or easy, and bears little or no relation to 
trial evidence or national guidelines. Therefore, many antibiotic courses 
are prescribed for ≥1 week. For example, experience from our ABS 
programme at Groote Schuur Hospital indicated that the vast majority of 
patients in the Emergency Department who were prescribed ceftriaxone 
received a prescription for an antibiotic for 2 weeks, irrespective of the 
indication (M Mendelson – unpublished observations). Unfortunately, 
a strong evidence base for antibiotic duration is often lacking, meaning 
that decisions are based not on randomised controlled trials, but on 
small observational studies or expert opinion. In SA, the Essential 
Drugs List (EDL) and Structured Treatment Guidelines (STGs)[34] 
Box 1. Checklist for optimal antibiotic prescribing 
1. Drug – which is the narrowest spectrum antibiotic that I can use to treat this bacterial infection? 
2. Dose – many antibiotics require weight-based dosing and their dosing depends on renal and/or  hepatic function
3.  Dose frequency – dependent on the half-life of the drug and whether the action of the antibiotic  depends on the time above the MIC or the area under the 
concentration/time curve. Calculation of the dosing frequency may require therapeutic drug monitoring, such as for vancomycin or aminoglycosides
4.  Duration – should be dictated by evidence from randomised controlled trials whenever possible. Expert opinion from national and international 
guidelines should be consulted where evidence is weak 
5.  Route – most antibiotics have good oral bioavailability, but some infections will require intravenous therapy either for the whole or part of the course
6.  De-escalation – applies to the spectrum of antibiotic use and route of administration. All attempts to convert early from parenteral to oral use should be made
MIC = minimum inhibitory concentration.
Box 2. Vancomycin dosing
All patients should be weighed and GFR estimated
All patients should receive a loading dose of 25 - 30 mg/kg
All subsequent doses should be 10 - 15 mg/kg (unless inadequate trough levels achieved)
Dosing interval and measurement of trough concentrations depends on eGFR
eGFR (mL/min) Dosing interval (hours) Measurement of trough concentrations
>80 12 Before 3rd dose
50 - 79 24 Before 3rd dose
55 - 49 36 Before 2nd dose
25 - 34 48 Before 2nd dose
<25, haemodialysis or chronic ambulatory 
peritoneal dialysis
When trough level 
<15 mg/mL
3 days after loading dose
Aim for trough concentration of 10 - 20 mg/mL, except for osteitis or endocarditis, or if MIC >1 mg/mL, when trough should be 15 - 20 mg/mL
If trough is too low – increase the dose
If trough is too high – increase the dosing interval
eGFR = estimated glomerular filtration rate.
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may guide prescribers. The SA Antibiotic 
Stewardship Programme (SAASP) guidelines 
for antibiotic prescribing in adults,[35] which 
is aligned to the EDL and STGs, provide an 
algorithmic approach to prescribing and 
further information on treatment duration. 
It is now available as the ‘SAASP’ App across 
platforms.
The route of administration of an antibiotic 
depends on the site of infection, how rapidly 
high drug levels need to be achieved, and 
ability of a patient to absorb an oral antibiotic. 
Some infections, such as bacterial meningitis, 
osteomyelitis or endocarditis, require high 
levels of antibiotic to be delivered to the 
site of infection, and necessitate parenteral 
antibiotics for all or the majority of the course. 
De-escalation to an oral antibiotic is a key 
principle of stewardship, as this obviates 
the need for vascular access and enables 
removal of a peripheral or central line. This 
reduces the risk of central line-associated 
bloodstream infections (CLABSI) or its 
peripheral counterpart. Prevention of CLABSI 
reduces morbidity, length of hospital stay and, 
ultimately, mortality.[36] Box 3 gives guidance 
for safe de-escalation from the parenteral to 
oral route. 
Antibiotic stewardship at 
the programmatic level
At a programmatic level, interventions to 
reduce antibiotic prescribing and improve 
microbial outcome tend to be either 
restrictive (limit how a prescriber prescribes) 
or persuasive (advise the prescriber or give 
feedback about how they prescribed). 
Approximately 80% of antibiotics used in 
humans are prescribed in primary care.[37,38] The 
success of interventions at the community level 
depends in part on the barriers to change in that 
particular community and differs in countries 
and across borders. A meta-analysis of 39 studies 
of interventions to improve antibiotic prescribing 
in ambulatory patients concluded that multi-
faceted interventions are most effective at 
achieving overall reduction in use, while printed 
educational material or feedback and audit 
were of little value.[39] Interactive educational 
sessions outperformed the didactic approach, 
and collaborative educational meetings between 
different groups involved in prescribing, i.e. 
a multidisciplinary community stewardship 
approach, showed promising reductions in 
antibiotic prescribing.[40] Combining teaching 
of primary care clinicians in enhanced 
consulting skills and the introduction of POC 
CRP into their practices, had an additive effect 
on appropriate, safe antibiotic prescribing, 
which was cost-effective.[28,41] The use of delayed 
prescriptions effectively reduced antibiotic use 
without increasing mortality.[42-44] All of these 
interventions are potentially transferable to 
LMICs, including SA.
Successful interventions to reduce 
prescribing in hospitalised patients have also 
been the subject of a Cochrane review.[45] 
Poor study designs in many investigations 
limited the number of studies included in 
the analysis to 20%. There were no direct 
comparative studies between persuasive 
and restrictive interventions, but a meta-
analysis of interrupted time series studies 
allowed comparison. Interestingly, restrictive 
interventions (compulsory order forms, 
expert approval, removal by restriction and 
review and change) were more effective than 
persuasive (dissemination of educational 
material, reminders, audit and feedback, and 
educational outreach) interventions in the 
first 6 months; yet, there was no difference in 
the longer term at 12 and 24 months. Whether 
combinations of intervention type would have 
a sustained effect needs to be investigated.
It is notable that none of the studies 
included in the Cochrane review was from 
Africa. ABS has only recently been formally 
introduced in SA as a change mechanism, led 
by SAASP since 2012. One study published to 
date has adopted two persuasive interventions 
to augment restrictive practices that were 
already in place at a central hospital in Cape 
Town;[32] ABS ward rounds and a dedicated 
antibiotic prescription chart were included 
in a trial in two general medical wards for 
a 12-month period, using the previous 
intervention-free year as comparator. Weekly 
multidisciplinary ward rounds involved the 
prescribing physicians, an infectious diseases 
specialist, microbiologist, infection control 
officer, and pharmacist. The charts and case 
Box 3. Criteria for switching from parenteral to oral antibiotic route[61,62] 
1.  No indication requiring long-term parenteral antibiotic use: endocarditis, meningitis, central nervous system infection, osteomyelitis, prosthetic 
material infection, Staphylococcus aureus bacteraemia, undrained or undrainable abscess and neutropenic fever
2. Patient is able to take oral medications and lacks indications of potential malabsorption
3. An alternative oral antibiotic is available
4. Temperature <38°C for ≥24 hours
5. Clinically improving or remaining stable
Fig. 2. South African Antibiotic Stewardship Programme prescription chart.
CONTINUING MEDICAL EDUCATION
418       May 2015, Vol. 105, No. 5
reports of each patient on a single ward, alternating weekly, were 
reviewed. Antibiotic use was reduced by 19.6% without an increase in 
inpatient mortality or 30-day readmission rate. Although not a primary 
objective of the study, the intervention resulted in a 35% reduction 
in antibiotic budget. This type of multidisciplinary team is unlikely 
to be reproducible across SA and most developing country settings; 
however, a prescriber and pharmacist can form the nucleus of any such 
stewardship team.
A dedicated antibiotic prescription chart in the study by Boyles 
et al.[32] was designed to focus the prescriber’s attention on the 
indication for prescribing antibiotics, whether the infection was 
community or hospital acquired, and provided strong messaging 
to trigger appropriate sample(s) to be sent for culture (Fig. 2). 
Antibiotic prescribing was divided into infection episodes – if a 
patient developed a second or third bacterial infection in hospital, the 
prescriber would have to go through the same process again, and the 
antibiotics used to treat that infection could immediately be identified 
for review and audit. The use of choice architecture, which describes 
the way in which decisions can be influenced by how choices are 
presented,[46] was recently used to improve anti-infective prescribing 
in a comparative study from a large UK teaching hospital.[47] 
Through its national strategic plan for AMR,[48] SA has national 
core standards for antimicrobial stewardship (and for infection 
prevention control) that will be monitored by the Office of Health 
Standards and Compliance. These standards include the requirement 
for stewardship committees and teams in all our hospitals and at 
district level. A clear roadmap for change is being implemented. 
Barriers to antibiotic stewardship
Behaviour modification is a major factor in rectifying poor prescribing 
practice. Inappropriate prescribing is driven by a complex set of 
prescriber and patient behaviours. At the most basic level, community 
prescribing is often influenced by prescribers who perceive that their 
patients will be dissatisfied should they not receive an antibiotic. This 
is especially evident in how doctors perceive parental expectations.[49] 
Patient expectations of receiving an antibiotic, particularly for ARI, is 
often high, and these have a significant influence on prescribing, even 
when the prescriber believes that an antibiotic is unnecessary.[50,51] 
Raising public awareness to the risks posed and drivers of ABR 
is an important intervention. Yet, not all campaigns have been 
successful;[52] national campaigns in different European countries 
have had mixed results, with those in Germany, Spain, Greece and 
the UK being unsuccessful in leading to important reductions in 
community antibiotic use or knowledge about appropriate use, as 
opposed to those in Sweden, Norway, France and Belgium. Successful 
national campaigns are characterised by a multifaceted nature and 
repetition over several years. Unfortunately, there seems to be no 
simple relationship between knowledge and appropriate use; in a 
face-to-face household survey of 10 981 randomly selected UK adults 
in 2003, multivariate analysis found that better knowledge in women 
was associated with being more likely to give an antibiotic to someone 
else for whom it was not prescribed.[53] This endorses the fact that 
behaviour change is complex and more than merely about providing 
information.
In terms of creating public behavioural change, despite media 
campaigns being more successful at disseminating information, 
medical professionals are more successful in changing patient 
behaviour.[54] Potential behavioural changes in community prescribers 
include improving their belief in the consequences of overprescribing 
and addressing their concerns around the consequences of not 
prescribing. Encouraging patients to adopt self-care for symptomatic 
relief of URTIs by consulting pharmacists instead of requesting 
antibiotics from doctors and greater mentoring of patients on their 
antibiotic use have the potential for creating change in antibiotic use 
at the community level. 
To enable good stewardship, prescribers must have access to affordable 
antibiotics of assured quality. Producing a new antibiotic pipeline is not in 
itself the answer to the ABR problem, as resistance has developed within 
16 years of every antibiotic introduced to date;[55] penicillin resistance was 
first identified 3 years before the antibiotic was introduced. However, lack 
of access to antibiotics is a major cause of mortality, mainly in children <5 
years of age, of whom more currently die of pneumonia owing to a lack of 
available treatment than of ABR. Substandard and falsified antimicrobials 
have undermined prescribing in these countries, as has the lack of affordable 
medicines, whereas the use of generic medicines has successfully driven 
down cost.[56] Generics  produced locally to rigorous good manufacturing 
practice standards may enhance access to quality-assured antibiotics and 
thus save lives.[57-59] A strong medicine regulatory authority is a prerequisite 
to ensure the success of a generic antimicrobial policy. 
Conclusion
The development of ABR cannot be prevented, but the extent to which 
it impacts on modern medicine can be altered through access to 
assured-quality, affordable antibiotics used in an appropriate manner. 
The onus is on every prescriber to become an antibiotic steward, 
ensuring that an antibiotic is only prescribed for a bacterial infection 
that requires treatment, and that the use of that antibiotic is optimised 
at an individual patient level. Programmatically, ABS must be developed 
as part of a national plan along with enhanced surveillance, reporting 
and infection prevention initiatives. Behavioural change programmes 
aimed at supporting prescribers and changing patient expectations are 
critical interventions, as is the need for increased access to diagnostic 
services and the development of POC or near-POC rapid diagnostics 
that couple pathogen and resistance information. 
If we are to alter the course of history, and prevent a situation where 
10 million people die annually from antibiotic-resistant infections by 
2050,[60] prescribers and public alike need to join the international 
community in change to preserve this precious resource.
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